Goal-directed therapy in osteoporosis

Journal of Bone and Mineral Research

Volumn 28, Issue 3, 2013, Pages 439-441

  McCloskey, Eugene ^a   Leslie, William D ^b  

^a NORTHERN GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

BONE DENSITY; BONE TURNOVER; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HUMAN; HYPERCHOLESTEROLEMIA; NOTE; OSSIFICATION; OSTEOPOROSIS; RISK ASSESSMENT; SMOKING CESSATION;

HUMANS; OSTEOPOROSIS;

EID: 84873949250     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1859     Document Type: Note

References (24)

1. Kanis JA., on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. Sheffield, UK: WHO Collaborating Centre, University of Sheffield.
2. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, McMahon M, Patkar NM, Volkmann E, Saag KG., American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010 Nov; 62 (11): 1515-1526.
3. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, Kvern B, Siminoski K, Leslie WD., Scientific Advisory Council of Osteoporosis Canada. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ. 2010 Nov 23; 182 (17): 1864-1873.
4. Compston J, Cooper A, Cooper C, Francis R, Kanis JA, Marsh D, McCloskey EV, Reid DM, Selby P, Wilkins M., Guidelines for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK. Maturitas. 2009; 62: 105-108.
5. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, Cooper C, Diez Perez A, Eastell R, Hofbauer LC, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE., Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep; 23 (9): 2257-2276.
6. Dawson-Hughes B, Looker AC, Tosteson AN, Johansson H, Kanis JA, Melton LJ 3rd., The potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005-2008. Osteoporos Int. 2012; 23: 811-820.
7. Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM., Goal-directed treatment of osteoporosis. J Bone Miner Res. 2013; 28: 433-438.
8. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D., Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA. 2000; 283: 1318-1321.
9. Bell KJ, Hayen A, Macaskill P, Irwig L, Craig JC, Ensrud K, Bauer DC., Value of routine monitoring of bone mineral density after starting bisphosphonate treatment: secondary analysis of trial data. BMJ. 2009; 338: b2266.
10. Funck-Brentano T, Biver E, Chopin F, Bouvard B, Coiffier G, Souberbielle JC, Garnero P, Roux C., Clinical utility of serum bone turnover markers in postmenopausal osteoporosis therapy monitoring: a systematic review. Semin Arthritis Rheum. 2011; 41: 157-169.
11. Compston J., Monitoring bone mineral density during antiresorptive treatment for osteoporosis. BMJ. 2009; 338: b1276.
12. Eastell R, Hannon RA., Biomarkers of bone health and osteoporosis risk. Proc Nutr Soc. 2008; 67: 157-162.
13. Watts NB, Lewiecki EM, Bonnick SL, Laster AJ, Binkley N, Blank RD, Geusens PP, Miller PD, Petak SM, Recker RR, Saag KG, Schousboe J, Siris ES, Bilezikian JP., Clinical value of monitoring BMD in patients treated with bisphosphonates for osteoporosis. J Bone Miner Res. 2009; 24: 1643-1646.
14. Schousboe JT, Bauer DC., Clinical use of bone turnover markers to monitor pharmacologic fracture prevention therapy. Curr Osteoporos Rep. 2012; 10: 56-63.
15. Gould AL, Davies GM, Alemao E, Yin DD, Cook JR., Cholesterol reduction yields clinical benefits: meta-analysis including recent trials. Clin Ther. 2007; 29: 778-794.
16. Chapurlat RD, Palermo L, Ramsay P, Cummings SR., Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial. Osteoporos Int. 2005; 16: 842-848.
17. Watts NB, Geusens P, Barton IP, Felsenberg D., Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J Bone Miner Res. 2005; 20: 2097-2104.
18. Delmas PD, Seeman E., Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone. 2004; 34: 599-604.
19. Sarkar S, Reginster JY, Crans GG, Diez-Perez A, Pinette KV, Delmas PD., Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004; 19: 394-401.
20. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM., Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002; 112: 281-289.
21. Austin M, Yang YC, Vittinghoff E, Adami S, Boonen S, Bauer DC, Bianchi G, Bolognese MA, Christiansen C, Eastell R, Grauer A, Hawkins F, Kendler DL, Oliveri B, McClung MR, Reid IR, Siris ES, Zanchetta J, Zerbini CA, Libanati C, Cummings SR., FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. J Bone Miner Res. 2012 Mar; 27 (3): 687-693.
22. Jacques RM, Boonen S, Cosman F, Reid IR, Bauer DC, Black DM, Eastell R., Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012; 27: 1627-1634.
23. Vasikaran S, Eastell R, Bruyere O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA., Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int. 2011; 22: 391-420.
24. Bauer D, Krege J, Lane N, Leary E, Libanati C, Miller P, Myers G, Silverman S, Vesper HW, Lee D, Payette M, Randall S., National Bone Health Alliance Bone Turnover Marker Project: current practices and the need for US harmonization, standardization, and common reference ranges. Osteoporos Int. 2012; 23: 2425-2433.